This article reviews the ocular adverse events associated with MEK inhibitor therapy for advanced cancers, with a particular focus on MEK inhibitor-associated retinopathy, and reports clinical experience and best practice approaches to management. This evidence concerns the gene MAP2K7 and cancer.